MIRA Pharmaceuticals, Inc. develops oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic and inflammatory disorders. Recurring company news centers on Ketamir-2, a selective oral NMDA receptor modulator studied for neuropathic pain, including chemotherapy-induced peripheral neuropathy, and on clinical safety, tolerability and pharmacokinetic findings from Phase 1 testing.
Updates also cover Mira-55, a cannabinoid analog designed to modulate CB1 and CB2 receptor activity while limiting central nervous system side effects, with preclinical work in inflammatory pain. Following the completed acquisition of SKNY Pharmaceuticals, MIRA’s pipeline also includes SKNY-1 for obesity and nicotine addiction. Company announcements additionally address shareholder voting matters, operating and financial results, capital actions and other corporate developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.